PELMEG

This brand name is authorized in Austria, Cyprus, Estonia, Finland, France, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug PELMEG contains one active pharmaceutical ingredient (API):

1	Pegfilgrastim UNII 3A58010674 - PEGFILGRASTIM
	Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes.
	Read more about Pegfilgrastim

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
PELMEG Solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AA13	Pegfilgrastim	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors
Discover more medicines within L03AA13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1782996
ES	Centro de información online de medicamentos de la AEMPS	1181328001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	182953
FR	Base de données publique des médicaments	61378153
GB	Medicines & Healthcare Products Regulatory Agency	365895
LT	Valstybinė vaistų kontrolės tarnyba	1086623
NL	Z-Index G-Standaard	15007219
NL	Z-Index G-Standaard, PRK	68756
PL	Rejestru Produktów Leczniczych	100413957
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66956001